VERAXA Biotech AG (NASDAQ: VRXA) has appointed Carl von Halem as interim chief financial officer, succeeding Torsten Bürgermeister, the company announced today. Von Halem, who currently serves as CFO of Xlife Sciences, played a key role in VERAXA’s public listing and brings extensive experience in corporate finance, life sciences, and technology-driven businesses. The company stated that it is in the final stages of discussions with a permanent CFO candidate expected to support its next phase of expansion and operational growth, with an update to be provided in due course.
Von Halem’s familiarity with VERAXA’s operations and strategic development was cited as a key qualification for leading the finance function during this transition period. The appointment comes as VERAXA advances its pipeline of antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company is powered by transformative technologies and guided by rigorous quality-by-design principles, aiming to rapidly progress its ADCs and proprietary BiTAC formats into clinical development and beyond.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company’s focus on next-generation antibody-based therapeutics positions it in a competitive biotech landscape, where interim leadership changes can signal strategic realignments or growth phases. Investors and industry watchers will be monitoring the permanent CFO appointment, as it is expected to play a crucial role in VERAXA’s operational and financial strategy moving forward.
For more details, the full press release is available at https://nnw.fm/BjjY6. The latest news and updates relating to VRXA can be found in the company’s newsroom at http://nnw.fm/VRXA.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is VERAXA Biotech Appoints Carl von Halem as Interim CFO Amid Permanent Candidate Search.